New Zealand approves cannabinoid Sativex for MS spasticity
This article was originally published in Scrip
MedSafe, the New Zealand regulatory authority, has approved Sativex (nabiximols), the cannabinoid spray product from GW Pharmaceuticals, to treat spasticity due to multiple sclerosis (MS). A consent notice to distribute Sativex under Section 20 of the Medicines Act 1981 has been published in the New Zealand Gazette, the official newspaper of the Government of New Zealand.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.